Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21687633)

  • 1. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
    Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
    PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.
    Zhang N; Wang X; Huo Q; Li X; Wang H; Schneider P; Hu G; Yang Q
    J Biol Chem; 2013 Mar; 288(13):9396-407. PubMed ID: 23408429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
    Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun SY
    PLoS One; 2010 Apr; 5(4):e10376. PubMed ID: 20442774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
    Symanowski J; Vogelzang N; Zawel L; Atadja P; Pass H; Sharma S
    J Thorac Oncol; 2009 Feb; 4(2):149-60. PubMed ID: 19179889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
    Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
    Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
    Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
    Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
    Zhou W; Feng X; Han Han ; Guo S; Wang G
    Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modification restores functional PR expression in endometrial cancer cells.
    Yang S; Xiao X; Jia Y; Liu X; Zhang Y; Wang X; Winters CJ; Devor EJ; Meng X; Thiel KW; Leslie KK
    Curr Pharm Des; 2014; 20(11):1874-80. PubMed ID: 23888956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
    Edwards A; Li J; Atadja P; Bhalla K; Haura EB
    Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
    PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein.
    Meng X; Zhu D; Yang S; Wang X; Xiong Z; Zhang Y; Brachova P; Leslie KK
    J Biol Chem; 2012 Feb; 287(7):4485-91. PubMed ID: 22199357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.